Tumor size and cancer stage at diagnosis are key determinants of survival: small, early-stage cancers are more responsive to treatment, with better prognoses. The AI/ML-Based CADe/CADx showed high performance in detecting early lung cancer, high sensitivity for cancers of different stage, T-category and cell type, excellent cancer recall rate (>96.5%) on all cancer stages and t-categories. This CADe/CADx can assist in the accurate follow-up of suspicious lung nodules, optimizing the management of patients in lung cancer screening.

Presented at European Lung Cancer Congress in Paris.